119 related articles for article (PubMed ID: 2350575)
21. The combination of melphalan, cyclophosphamide and cytosine arabinoside as a conditioning regimen for autologous bone marrow transplantation for acute leukemia.
Wang C; Qiao Z; Yang L; Ma L; Zhang H; Zhang J
Chin Med J (Engl); 1996 Apr; 109(4):304-7. PubMed ID: 8758293
[TBL] [Abstract][Full Text] [Related]
22. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
23. Cryopreserved autologous bone marrow infusion following high dose chemotherapy in patients with acute myeloblastic leukemia in first relapse.
Meloni G; De Fabritiis P; Papa G; Amadori S; Pulsoni A; Simone F; Mandelli F
Leuk Res; 1985; 9(3):407-12. PubMed ID: 3889507
[TBL] [Abstract][Full Text] [Related]
24. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
Ho AD; Lipp T; Ehninger G; Illiger HJ; Meyer P; Freund M; Hunstein W
J Clin Oncol; 1988 Feb; 6(2):213-7. PubMed ID: 3422260
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
26. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission.
Schiller G; Lee M; Paquette R; Sawyers C; Khoubian F; Territo M
Leuk Lymphoma; 1999 May; 33(5-6):475-84. PubMed ID: 10342575
[TBL] [Abstract][Full Text] [Related]
27. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
Amadori S; Testi AM; Aricò M; Comelli A; Giuliano M; Madon E; Masera G; Rondelli R; Zanesco L; Mandelli F
J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
[TBL] [Abstract][Full Text] [Related]
28. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
29. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
[TBL] [Abstract][Full Text] [Related]
30. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation.
Philip T; Chauvin F; Armitage J; Bron D; Hagenbeek A; Biron P; Spitzer G; Velasquez W; Weisenburger DD; Fernandez-Ranada J
Blood; 1991 Apr; 77(7):1587-92. PubMed ID: 2009374
[TBL] [Abstract][Full Text] [Related]
31. BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results.
Capria S; Latagliata R; Avvisati G; Breccia M; Cimino G; Diverio D; Petti MC; Meloni G
Bone Marrow Transplant; 2005 Jul; 36(1):83-4. PubMed ID: 15880128
[No Abstract] [Full Text] [Related]
32. Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
Fouillard L; Labopin M; Meloni G; Polge E; Gorin NC; Frassoni F
Haematologica; 2004 Jan; 89(1):107-8. PubMed ID: 14754615
[No Abstract] [Full Text] [Related]
33. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
[TBL] [Abstract][Full Text] [Related]
34. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
35. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients).
Philip T; Chauvin F; Bron D; Guglielmi C; Hagenbeek A; Coiffier B; Gisselbrecht C; Kluin Nelemans JC; Somers R; Misset JC
Ann Oncol; 1991 Jan; 2 Suppl 1():57-64. PubMed ID: 2043500
[TBL] [Abstract][Full Text] [Related]
36. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
[TBL] [Abstract][Full Text] [Related]
37. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
Linker CA; Damon LE; Ries CA; Rugo HS; Wolf JL
Semin Oncol; 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. PubMed ID: 8342075
[TBL] [Abstract][Full Text] [Related]
38. Modified chemotherapy with carmustine, cytarabine, cyclophosphamide, and 6-thioguanine (BACT) and autologous bone marrow transplantation in 24 poor-risk patients with acute lymphoblastic leukemia.
Pico JL; Hartmann O; Maraninchi D; Beaujean F; Benhamou E; Mascret B; Novakovitch G; Ghalie R; Kalifa C; Hayat M
J Natl Cancer Inst; 1986 Jun; 76(6):1289-93. PubMed ID: 3520070
[TBL] [Abstract][Full Text] [Related]
39. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
40. Treatment of childhood acute myelogenous leukemia with allogeneic and autologous stem cell transplantation during the first remission: a report from the Kyushu-Yamaguchi Children's Cancer Study group in Japan.
Matsuzaki A; Eguchi H; Ikuno Y; Ayukawa H; Yanai F; Ishii E; Sugimoto T; Inada H; Anami K; Nibu K; Hara T; Miyazaki S; Okamura J
Pediatr Hematol Oncol; 2000 Dec; 17(8):623-34. PubMed ID: 11127394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
